References
- 1. CHEN LT., MARTINELLI E., CHENG AL., PENTHEROUDAKIS G., QIN S., BHATTACHARYYA GS., et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334–351.
- 2. HASAN I., SULAIMAN AS., GANI RA., LESMANA CR. Risk factors for hepatocellular carcinoma and its mortality rate: a multicenter study in Indonesia. Arch Cancer Res. 2019;7(1):2.
- 3. LOHO IM., SIREGAR L., WASPODO AS., HASAN I. Current practice of hepatocellular carcinoma surveillance. Acta Med Indones. 2018;50(4):353–360.
- 4. SHU H., LI W., SHANG S., QIN X., ZHANG S., LIU Y. Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1. Discov Med. 2017;23(126):163–168.
- 5. PAUL SB., GULATI MS., SREENIVAS V., MADAN K., GUPTA AK., MUKHOPADHYAY S., et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha- fetoprotein. J Oncol. 2007;72(suppl 1):117–123.
- 6. YANG JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25(4): 335–343
- 7. DUAN J., WU Y., LIU J., ZHANG J., FU Z., FENG T., et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J Hepatocell Carcinoma. 2019;6:151–166.
- 8. OCKER M. Biomarkers for hepatocellular carcinoma: what’s new on the horizon? World J Gastroenterol. 2018;24(35):3974–3979.
- 9. HODEIB H., ELSHORA O., SELIM A., SABRY NM., ELASHRY HM. Serum midkine and osteopontin levels as diagnostic biomarkers of hepatocellular carcinoma. Electron Physician. 2017;9(1):3492–3498.
- 10. WANG P., MAO YM., ZHAO CN., WANG JB., LI XM., YE DQ., et al. Association of midkine and pleiotrophin gene polymorphisms with systemic lupus erythematosus susceptibility in Chinese Han population. Front Immunol. 2020;11:110.
- 11. EI-EDEL RH., TAWFIK GA., NORELDIN RI., EL-JAKY MA., EISAA DA. Evaluation of serum midkine as a novel marker in hepatocellular carcinomas. Menoufia Med J. 2018;31(3):1094.
- 12. PARKIN DM., BRAY F., FERLAY J., PISANI P. Global cancer statistics, 2002. Ca-Cancer J Clin. 2005;55(2):74–108.
- 13. KINOSHITA A., ONODA H., FUSHIYA N., KOIKE K., NISHINO H., TAJIRI H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7(3): 406–424.
- 14. RICHANI M., KOLLY P., KNOEPFLI M., HERRMANN E., ZWEIFEL M., TENGG-KOBLIGK HV., et al. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol. 2016;15(1):82–90.
- 15. MARRERO JA., KULIK LM., SIRLIN CB., ZHU AX., FINN RS., ABECASSIS MM., et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
- 16. TELLAPURI S., SUTPHIN PD., BEG MS., SINGAL AG., KALVA SP. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–491.
- 17. DOYLE A., SHERMAN M. Liver biopsy for hepatocelullar carcinoma (HCC): should this be a routine? Curr Hepatol Rep. 2017;16:46–50.
- 18. HNASKO R. ELISA: Methods and protocols. USA; New York: Humana Press, 2019.
- 19. WORLD HEALTH ORGANIZATION. World cancer report 2014. http://www.who.int// (accessed 23 May 2020)
- 20. BALOGH J., VICTOR III D., ASHAM EH., BURROUGHS SG., BOKTOUR M., SAHARIA A., et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3: 41–53.
- 21. MANIERI E., HERRERA-MELLE L., MORA A., TOMÁS-LOBA A., LEIVA-VEGA L., FERNÁNDEZ DI., et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216(5):1108–1119.
- 22. SAXENA NK., FU PP., NAGALINGAM A., WANG J., HANDY J., COHEN C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. J Gastroenterol. 2010;139(5):1762–1773.
- 23. TANGKIJVANICH P., MAHACHAI V., SUWANGOOL P., POOVORAWAN Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10(11): 1547–1550.
- 24. EL-SERAG HB., RUDOLPH KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. J Gastroenterol. 2007;132:2557–2576.
- 25. MAZZAFERRO V., REGALIA E., DOCI R., ANDREOLA S., PULVIRENTI A., BOZZETTI F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.
- 26. TAKAYAMA T., MAKUUCHI M., KOJIRO M., LAUWERS GY., ADAMS RB., WILSON SR., et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15:972–978.
- 27. KO YS., BAE JH., SINN DH., GWAK GY., KANG W., PAIK YH., et al. The clinical significance of serum alpha-fetoprotein in diagnosing hepatocellular carcinoma in a health screening population. Korean J Gastroenterol. 2017;69(4):232–238.
- 28. TZARTZEVA K., OBI J., RICH NE., PARIKH ND., MARRERO JA., YOPP A., et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. J Gastroenterol. 2018;154(6):1706–1718.
- 29. JING X., CUI X., LIANG H., HAO C., HAN C. Diagnostic accuracy of ELISA for detecting serum midkine in cancer patients. PLoS One. 2017;12(7): e0180511.
- 30. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10): e0223514.
- 31. VONGSUVANH R., VAN DER POORTEN D., ISELI T., STRASSER SI., MCCAUGHAN GW., GEORGE J. midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma. PLoS One. 2016;11(5): e0155800.
- 32. SHAHEEN KY., ABDEL-MAGEED AI., SAFWAT E., ALBREEDY AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int J Hepatol. 2015; 2015:146389.
- 33. NAULT J-C. Midkine as a new diagnostic tool in hepatocellular carcinoma. Transl Gastrointest Cancer. 2014;3(2):100–102.
- 34. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10):e0223514.
- 35. LU Q., CAO H., LV C., WANG X., CAO S. Comparison of diagnostic accuracy of midkine and AFP for detecting hepatocellular carcinoma: A systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20192424.
- 36. ZHAO ZQ., YANG S., LU HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 2012;5(2):415–419.
- 37. ZHU WW., GUO JJ., GUO L., JIA HL., ZHU M., ZHANG JB., et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944–3954.
- 38. SHIMADA H., NABEYA Y., TAGAWA M., OKAZUMI SI., MATSUBARA H., KADOMATSU K., et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94(7):628–632.